Mark Cunningham

A novel Escherichia coli lipid A mutant that produces an antiinflammatory lipopolysaccharide.

John E. Somerville, Luiza de Paula Silva Cassiano, Brian W. Bainbridge et al. · Journal of Clinical Investigation · 1996 · 272 citations · Full text

Microbial Pathogens, Immunology, Novel Escherichia Coli +23

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

James R. Burke, Lihong Cheng, Kathleen M. Gillooly et al. · Science Translational Medicine · 2019 · 268 citations

Ability of bacteria associated with chronic inflammatory disease to stimulate E-selectin expression and promote neutrophil adhesion

Richard P. Darveau, Mark Cunningham, Tina S. Bailey et al. · Infection and Immunity · 1995 · 162 citations · Full text

Chronic Inflammatory Diseases, Immunology, Oral Microbiology +19

Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer

Nataly Manjarrez‐Orduño, Laurence Ménard, Selena Kansal et al. · Frontiers in Immunology · 2018 · 123 citations · Full text

Beta-lactam antibiotics potentiate magainin 2 antimicrobial activity in vitro and in vivo

Richard P. Darveau, Mark Cunningham, Carrie L. Seachord et al. · Antimicrobial Agents and Chemotherapy · 1991 · 101 citations · Full text

Magainin 2, Escherichia Coli, Antimicrobial Chemotherapy +20